SYDNEY, AUSTRALIA – October 10, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”),
a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is
pleased to announce that it has received a €1,568,399 (~$2,546,929) research and development (R&D) tax incentive payment in cash from the French Government under its Cre´dit d’Impo^t Recherche scheme (CIR).
For further information please download the attached PDF:
Download this document
